What’s new in diagnosis and therapy in haematology and haematological oncology?

Wiesław Wiktor Jędrzejczak

ISSN: 1505-8409

Przewodnik Lekarza/Guide for GPs

Current issue Archive About the journal Supplements Contact Instructions for authors

1/2009
vol. 12

Send email

Copy url:

abstract:

What’s new in diagnosis and therapy in haematology and haematological oncology?

Wiesław Wiktor Jędrzejczak

Przew Lek 2009; 1: 118-125

Online publish date: 2009/03/18

View full text Get citation

In this review the main principles of WHO classification of tumours of haematopoietic and lymphoid tissues are discussed and consequences of introduction of this classification for change of diagnostic and therapeutic standards are outlined. Several disorders are currently diagnosed exclusively based on cytogenetic and molecular analysis, which therefore have become part of routine diagnostic management. Moreover, molecular definition has allowed the introduction in some neoplasms of therapy targeted at molecular change characteristic for a given disease. Such an approach is the most advanced in chronic myelocytic leukaemia, where three targeted drugs (imatinib, dasatinib, and nilotinib) are available, but studies concerning other leukaemias and lymphomas are also very advanced.

keywords:

What’s new in diagnosis and therapy in haematology and haematological oncology?

Wiesław Wiktor Jędrzejczak

WHO classification, targeted therapy, blood neoplasms